Ranibizumab Biosimilar Shows Equivalent Efficacy to Branded Drug for Neovascular AMD

In a phase 3 study, the ranibizumab biosimilar SB11 demonstrated equivalent efficacy and similar safety and immunogenicity profiles compared with ranibizumab for patients with neovascular age-related macular degeneration (nAMD).
Reuters Health Information

Source link